Save

Effects of conjugated oestrogens and aminocaproic acid upon exercise-induced pulmonary haemorrhage (EIPH)

In: Comparative Exercise Physiology
Authors:
T.S. Epp Department of Anatomy and Physiology, 228 Coles Hall, Kansas State University, Manhattan, KS 66506, USA

Search for other papers by T.S. Epp in
Current site
Google Scholar
PubMed
Close
,
K.L. Edwards Department of Anatomy and Physiology, 228 Coles Hall, Kansas State University, Manhattan, KS 66506, USA

Search for other papers by K.L. Edwards in
Current site
Google Scholar
PubMed
Close
,
D.C, Poole Department of Anatomy and Physiology, 228 Coles Hall, Kansas State University, Manhattan, KS 66506, USA

Search for other papers by D.C, Poole in
Current site
Google Scholar
PubMed
Close
, and
H.H. Erickson Department of Anatomy and Physiology, 228 Coles Hall, Kansas State University, Manhattan, KS 66506, USA

Search for other papers by H.H. Erickson in
Current site
Google Scholar
PubMed
Close
Download Citation Get Permissions

Access options

Get access to the full article by using one of the access options below.

Institutional Login

Log in with Open Athens, Shibboleth, or your institutional credentials

Login via Institution

Purchase

Buy instant access (PDF download and unlimited online access):

€36.93

Abstract

Aminocaproic acid (ACA) and Premarin® at the racetrack based upon their putative coagulation effects. We hypothesized that neither ACA nor PRE would reduce EIPH because the literature does not substantiate coagulation deficits being manifested in EIPH. Six Thoroughbreds were run from 4 m s−1 until fatigue (1 m s−1 × 1 min increments; 6 inclined treadmill) after being treated with placebo, PRE (25 mg) or ACA (5 g) at 2-week intervals in a randomized crossover design. Coagulation and exercise-related variables were measured at rest and maximal effort. EIPH and inflammation were quantified via bronchoalveolar lavage fluid (BALF) 30–60 min post-exercise. EIPH was not altered by either treatment (3.8 ± 1.7 (placebo), 4.6 ± 3.2 (ACA) and 2.4 ± 1.2 (PRE) × 106 RBC ml−1 BALF; p = 0.12), nor was coagulation. However, inflammation was decreased (5.9 ± 0.9 (placebo), 4.4 ± 0.9 (ACA) and 4.2 ± 0.4 (PRE) × 105 WBC ml−1 BALF; both p < 0.05). There was a trend for decreased time-to-fatigue (720 ± 27 (placebo), 709 ± 24 (ACA) and 726 ± 28 (PRE) s; p = 0.09 for placebo vs. ACA) and a reduction in plasma lactate (19.5 ± 3.0 (placebo), 14.7 ± 1.0 (ACA) and 17.6 ± 2.5 (PRE) mmol l−1; p < 0.05 for placebo vs. ACA) following ACA administration. ACA and PRE were not effective in reducing EIPH, and ACA may be detrimental to performance. However, both may mitigate exercise-induced pulmonary inflammation.

Content Metrics

All Time Past 365 days Past 30 Days
Abstract Views 56 24 12
Full Text Views 0 0 0
PDF Views & Downloads 5 0 0